Skip to main content
Fig. 2 | Infectious Agents and Cancer

Fig. 2

From: Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to rituximab

Fig. 2

Visual timeline including major clinical findings, treatments, virologic and laboratory data. a Clinical timeline and treatments in the context of results for SARS-CoV-2 RT-PCR and virus-specific IgG and IgM antibodies. ARDS severity was scored according to the Berlin definition. b, c Chest computed tomography scans (April 1, 2029) showing typical features of COVID-19 pneumonia with bilateral consolidative abnormalities, central and peripheral ground glass opacities. d RT-PCR results (Ct) vs. detection of anti SARS-CoV-2 IgG and IgM antibodies. RT-PCR data was obtained by using the Allplex™ 2019-nCoV multiplex Assay. IgG and IgM were evaluated by chemoluminiscence immunoassay (Shenzhen YHLO Biotech Co, Ltd) and results expressed in arbitrary units (AU)/mL. Cut off value for positivity as indicated by manufacturer was of 10 AU/mL both for IgM and IgG antibodies (e) Changes in serum levels of ferritin, IL-6 and ALC. Abbrevations used in the figures. FISH, fluorescence in situ hybridization; RT-PCR, reverse transcriptase-polymerase chain reaction (RT-PCR); BT, body temperature (°C); ARDS, acute respiratory distress syndrome; AU, arbitrary units; ALC, absolute lymphocyte counts; Ct, cycle threshold

Back to article page